Ascendis Pharma A/S Announces Participation in August Investor Conferences
July 29, 2019 08:00 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, July 29, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with Achondroplasia
July 18, 2019 16:12 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, July 18, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address significant unmet...
Ascendis Pharma A/S Announces R&D Day on June 26 to Review Endocrinology Rare Disease Pipeline and Introduce Oncology Programs
June 19, 2019 08:30 ET
|
Ascendis Pharma A/S
– Continued progress of all three global endocrinology rare disease programs – – Validation of TransCon™ platform in phase 3 heiGHt Trial paves way for new therapeutic areas, including oncology – ...
Ascendis Pharma A/S Reports First Quarter 2019 Financial Results
May 30, 2019 16:02 ET
|
Ascendis Pharma A/S
– Continued execution of global endocrinology rare disease programs, following validation of TransCon™ platform in phase 3 heiGHt Trial – – R&D Day on June 26 to feature endocrinology and...
Ascendis Pharma A/S Announces Preliminary Data from Single Arm Phase 3 fliGHt Trial Demonstrated TransCon™ hGH was Safe and Well-Tolerated in Pediatric Subjects Previously Treated with Daily Growth Hormone
May 20, 2019 07:30 ET
|
Ascendis Pharma A/S
- Provides real-world experience for switching pediatric growth hormone deficiency subjects one to 17 years old from daily growth hormone to once-weekly TransCon hGH - - Data included...
Ascendis Pharma A/S Announces First Quarter 2019 Financial Results and Business Update Conference Call on May 30
May 16, 2019 08:00 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, May 16, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Announces Participation in the Bank of America Merrill Lynch 2019 Healthcare Conference
May 07, 2019 16:02 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, May 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...
Ascendis Pharma A/S Announces Presentations Related to Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences
April 24, 2019 17:26 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, April 24, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical...
Ascendis Pharma A/S Reports Full Year 2018 Financial Results
April 03, 2019 16:01 ET
|
Ascendis Pharma A/S
– Rare disease endocrinology pipeline continues to advance, with significant 2019 milestones anticipated – – Phase 3 heiGHt Trial results showcase potential of TransCon™ technologies and support...
Ascendis Pharma A/S Announces Year-End 2018 Financial Results and Business Update Conference Call on April 3
March 27, 2019 17:00 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, March 27, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical...